Merino Diane, Gérard Alexandre O, Van Obberghen Elise K, Ben Othman Nouha, Ettore Eric, Giordana Bruno, Viard Delphine, Rocher Fanny, Destere Alexandre, Benoit Michel, Drici Milou-Daniel
Department of Psychiatry, University Hospital of Nice, 06000 Nice, France.
Department of Pharmacology and Pharmacovigilance Center of Nice, University Hospital of Nice, 06000 Nice, France.
J Clin Med. 2022 Jul 4;11(13):3890. doi: 10.3390/jcm11133890.
Sleep-related eating disorder (SRED) is a parasomnia with recurrent, involuntary, amnestic eating episodes during sleep. There is growing evidence of the association between SRED and medications. Therefore, we aimed to rank drugs showing the strongest association. VigiBase® (WHO pharmacovigilance database) was queried for all reports of “Sleep-related eating disorder”. Disproportionality analysis relied on the Reporting Odds Ratio, with its 95% Confidence Interval (CI), and the Information Component. Our VigiBase® query yielded 676 cases of drug-associated SRED. Reports mostly involved zolpidem (243, 35.9%), sodium oxybate (185, 27.4%), and quetiapine (97, 14.3%). Significant disproportionality was found for 35 medications, including zolpidem (387.6; 95%CI 331.2−453.7), sodium oxybate (204.2; 95%CI 172.4−241.8), suvorexant (67.3; 95%CI 38.0−119.2), quetiapine (53.3; 95%CI 43.0−66.1), and several psychostimulants and serotonin-norepinephrine reuptake inhibitors (SNRIs). Patients treated with nonbenzodiazepines or SNRIs were significantly older (mean age: 49.0 vs. 37.5; p < 0.001) and their SRED were more likely to be serious (62.6% vs. 51.4%; p = 0.014) than patients treated with sodium oxybate or psychostimulants. Psychotropic drugs are involved in almost all reports. In patients with SRED, an iatrogenic trigger should be searched for.
睡眠相关进食障碍（SRED）是一种异态睡眠，其特征为睡眠期间反复出现的、非自主性的、遗忘性的进食发作。越来越多的证据表明SRED与药物之间存在关联。因此，我们旨在对显示出最强关联的药物进行排名。我们在VigiBase®（世界卫生组织药物警戒数据库）中查询了所有“睡眠相关进食障碍”的报告。不成比例分析依赖于报告比值比及其95%置信区间（CI）以及信息成分。我们对VigiBase®的查询产生了676例药物相关的SRED病例。报告大多涉及唑吡坦（243例，35.9%）、羟丁酸钠（185例，27.4%）和喹硫平（97例，14.3%）。发现35种药物存在显著不成比例，包括唑吡坦（387.6；95%CI 331.2 - 453.7）、羟丁酸钠（204.2；95%CI 172.4 - 241.8）、苏沃雷生（67.3；95%CI 38.0 - 119.2）、喹硫平（53.3；95%CI 43.0 - 66.1）以及几种精神兴奋剂和5-羟色胺-去甲肾上腺素再摄取抑制剂（SNRI）。与接受羟丁酸钠或精神兴奋剂治疗的患者相比，接受非苯二氮䓬类药物或SNRI治疗的患者年龄显著更大（平均年龄：49.0岁对37.5岁；p < 0.001），且他们的SRED更有可能较为严重（62.6%对51.4%；p = 0.014）。几乎所有报告都涉及精神药物。对于SRED患者，应寻找医源性触发因素。
